Clovis Oncology (NASDAQ:CLVS) announced updated findings from the Phase 1 portion of its ongoing Phase 1/2 clinical study of CO-1686, the Company’s novel, oral, targeted covalent (irreversible) inhibitor of mutant forms of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer in patients with initial activating EGFR mutations as well as the dominant resistance mutation T790M. Interim results from the Phase 1 dose-escalation portion of this Phase 1/2 study are being presented in an oral presentation by Dr. Heather Wakelee at the 4th European Lung Cancer Conference (ELCC) in Geneva. Clovis Oncology Inc (NASDAQ:CLVS) shares after opening at $75.15 on last trade day and at the end of the day closed at $77.50. Company price to cash ratio in past twelve months was calculated as 7.64. Clovis Oncology Inc (NASDAQ:CLVS) showed a negative weekly performance of -10.67%.
Investment analysts at Morgan Stanley initiated coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a note issued to investors on Wednesday, StockRatingsNetwork reports. The firm set an “equal weight” rating on the stock. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares fell -0.14% in last trading session and ended the day on $308.43. REGN return on equity ratio is recorded as 25.90% and its return on assets is 16.60%. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) yearly performance is 81.74%.
Epizyme Inc (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers on Feb. 27, 2014 announced 2013 operating and financial results and provided 2014 guidance. Epizyme Inc (NASDAQ:EPZM) shares moved down -2.97% in last trading session and was closed at $22.90, while trading in range of $22.59 – $24.04. Epizyme Inc (NASDAQ:EPZM) year to date (YTD) performance is 10.10%.
March 24, 2014 — Kandi Technologies Group Inc (NASDAQ:KNDI), announced that it has closed the registered direct placement with two institutional investors and raised approximately $11.05 million from selling its common stock shares at a price of $18.24 per share. The Company issued a total of 606,000 shares to the institutional investors. As part of the transaction, the Company also issued to the investors Warrants for the purchase of up to 90,900 shares of common stock at an exercise price of 22.80 per share, which warrants have a term of 18 months from the date of issuance. Kandi Technologies Group Inc (NASDAQ:KNDI) weekly performance is -14.81%. On last trading day company shares ended up $16.22. Kandi Technologies Group Inc (NASDAQ:KNDI) distance from 50-day simple moving average (SMA50) is 6.62%. Analysts mean target price for the company is $4.59.